Joint Formulary & PAD

Entacapone - Parkinson's disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important
Preferred

Preferred COMT inhibitor

Primary Care can initiate treatment on specialist recommendation

Documentation

PAD Profile

ChemicalSubstance :
Entacapone
Indication :
Parkinson's disease
Group Name :
Keywords :
Parkinsons disease, PD, COMT inhibitors, catechol-o-methyltransferase inhibitors
Brand Names Include :
Comtess
Important Information :
Latest Additions Date From :
13 Feb 2026
Latest Additions Date To :
13 Mar 2026
Guidelines :
Supporting Documents :
1

Committee Recommendations (2)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed a change in traffic light status for entacapone  from BLUE (with specialist team initiation) to BLUE (on specialist team recommendation), used in the treatment of Parkinson’s disease.

COMT inhibitors are a choice of adjuvant treatment in patients who have developed dyskinesia or motor fluctuations despite optimal levodopa therapy.

  • Entacapone is the locally agreed 1st-choice COMT inhibitor (BLUE no information sheet)
  • Opicapone is the locally agreed 2nd-choice COMT inhibitor (BLUE no information sheet)
  • Tolcapone is the locally agreed 3rd-choice COMT inhiitor (AMBER shared care)

Prescribers are reminded to prescribe generically and not by brand.